Ge Long Hui·2025-12-29 08:55Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration certificate of its injection product, Benzyl Alcohol Injection, which is intended for treating acute spasmodic pain caused by digestive system and biliary dysfunction, as well as acute spasmodic pain in the urinary tract, bladder, and kidney, and gynecological spasmodic pain [1] Company Summary - The company has announced the approval of Benzyl Alcohol Injection, which expands its product offerings in the pharmaceutical market [1] - This product is specifically designed to address various types of acute spasmodic pain, indicating a focus on pain management solutions [1] Industry Summary - The approval of new pharmaceutical products like Benzyl Alcohol Injection reflects ongoing developments in the healthcare sector, particularly in pain management therapies [1] - The market for treatments addressing acute spasmodic pain is significant, highlighting potential growth opportunities for companies in this segment [1]